Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2023

Open Access 01-12-2023 | Multiple Sclerosis | Research

The role of systemic ımmune ınflammatory ındex in showing active lesion ın patients with multiple sclerosis

SII and other inflamatuar biomarker in radiological active multiple sclerosis patients

Authors: Seyda Figul Gokce, Asli Bolayır, Burhanettin Cigdem, Bulent Yildiz

Published in: BMC Neurology | Issue 1/2023

Login to get access

Abstract

Background

Multiple sclerosis (MS) has two pathophysiological processes, one inflammatory and the other degenerative. We investigated the relationship between active lesions on magnetic resonance imaging showing the inflammatory phase in MS patients and serum parameters that can be used as inflammatory biomarkers. Thus, we aim to detect the inflammatory period in clinical and radiological follow-up and to reveal the period in which disease-modifying treatments are effective with serum parameters.

Methods

One hundred eighty-six MS patients presented to our hospital between January 2016 and November 2021 and 94 age- and sex-matched healthy volunteers were recruited for our study. While 99 patients had active lesions on magnetic resonance imaging, 87 patients did not have any active lesions. Neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and monocyte/lymphocyte ratio (MLR) were determined. The SII (systemic immune inflammatory index) value was calculated according to the platelet X neutrophil/lymphocyte ratio formula.

Results

NLR, MLR, PLR and SII values were found to be statistically significantly higher in MS patients than in the control group. The NLR, MLR, PLR and SII were higher in the active group with gadolonium than in the group without active lesions. In addition, the cutoff values that we can use to determine the presence of active lesions were 1.53, 0.18, 117.15, and 434.45 for NLR, MLR PLR and SII, respectively.

Conclusions

We found that all parameters correlated with radiological activity. In addition, we showed that we can detect the inflammatory period with high sensitivity and specificity with the cutoff value used for SII and PLR. Among these easily accessible and inexpensive evaluations, we concluded that SII, including the values in the PLR formula, can come to the fore.
Literature
1.
2.
3.
4.
Tintore M, Angela VJ, Sastre-Garriga J. Treatment of multiple sclerosis-success from bench to bedside. Nature Reviews Neurology. 2019;15(1):53–8.CrossRefPubMed
5.
Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343(20):1430–8.CrossRefPubMed
6.
Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med. 2006;354(9):942–55.CrossRefPubMed
7.
Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol. 2007;7(2):161–7.CrossRefPubMed
8.
9.
Guzel I, Mungan S, Oztekin ZN, Fikri Ak. Is there an association between the Expanded Disability Status Scale and inflammatory markers in multiple sclerosis? J Chin Med Assoc. 2016;79(2):54–7.CrossRefPubMed
10.
Gong P, Liu Y, Gong Y, Chen G, Zhang X, Wang S, et al. The association of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and lymphocyte to monocyte ratio with post-thrombolysis early neurological outcomes in patients with acute ischemic stroke. J Neuroinflammation. 2021;18(1):51.CrossRefPubMedPubMedCentral
11.
Wang L, Wang C, Jia X, Yang M, Yu J. Relationship between Neutrophil-to-Lymphocyte Ratio and Systemic Lupus Erythematosus: A Meta-analysis. Clinics (Sao Paulo). 2020;17(75):e1450.CrossRef
12.
Lianos GD, Alexiou GA, Exarchos C, Rausei S, Mitsis M, Voulgaris S. Prognostic significance of neutrophil-to-lymphocyte ratio in several malignancies: where do we stand? Biomark Med. 2020;14(3):169–72.CrossRefPubMed
13.
Gelibter S, Pisa M, Croese T, Dalla Costa G, Orrico M, Preziosa P, et al. Neutrophil-to-lymphocyte ratio: a marker of neuro-inflammation in multiple sclerosis? J Neurol. 2021;268(2):717–23.CrossRefPubMed
14.
Hemond CC, Glanz BI, Bakshi R, Chitnis T, Healy BC. The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis. BMC Neurology. 2019;19(1):1–10.CrossRef
15.
López PA, Criniti J, Pettinicchi JP, Cristiano E, Patrucco L, Lazaro L, et al. Platelet-to-lymphocyte ratio differs between MS and NMOSD at disease onset and predict disability. Mult Scler Relat Disord. 2022;58:103507.CrossRefPubMed
16.
Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212–22.CrossRefPubMed
17.
Kim Y, Choi H, Jung SM, Song JJ, Park YB, Lee SW. Systemic immune-inflammation index could estimate the cross-sectional high activity and the poor outcomes in immunosuppressive drug-naïve patients with antineutrophil cytoplasmic antibody-associated vasculitis. Nephrology (Carlton). 2019;24(7):711–7.CrossRefPubMed
18.
Pasquini L, Napolitano A, Visconti E, Longo D, Romano A, Tomà P, et al. Gadolinium-based contrast agent-related toxicities. CNS Drugs. 2018;32(3):229–40.CrossRefPubMed
19.
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–73.CrossRefPubMed
20.
Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4):655–61.
21.
Kolcava J, Hulova M, Rihova L, Bednarik J, Stourac P. The impact of lymphocytosis and CD4/CD8 ratio on the anti-JCV antibody index and clinical data in patients treated with natalizumab. Neurol Sci. 2021;42(7):2847–53.CrossRefPubMed
22.
Demirci S, Demirci S, Kutluhan S, Koyuncuoglu HR, Yurekli VA. The clinical significance of the neutrophil-to-lymphocyte ratio in multiple sclerosis. Int J Neurosci. 2016;126(8):700–6.PubMed
23.
Faul F, Erdfelder E, Buchner A, et al. Statistical power analyses using G*Power 31: Tests for correlation and regression analyses. Behav Res Methods. 2009;41:1149–60.CrossRefPubMed
24.
Giovannoni G, Miller D, Losseff N, Sailer M, Lewellyn-Smith N, Thompson AJ, et al. Serum inflammatory markers and clinical/MRI markers of disease progression in multiple sclerosis. J Neurol. 2001;248:487–95.CrossRefPubMed
25.
Bisgaard AK, Pihl-Jensen G, Frederiksen JL. The neutrophil-to-lymphocyte ratio as disease actvity marker in multiple sclerosis and optic neuritis. Mult Scler Relat Disord. 2017;18:213–7.CrossRefPubMed
26.
D’Amico E, Zanghì A, Romano A, Sciandra M, Palumbo GAM, Patti F. The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis. Cells. 2019;8(10):1114.CrossRefPubMedPubMedCentral
27.
Yetkin MF, Mirza M. Neutrophil to-lymphocyte ratio as a possible predictor of prognosis in recently diagnosed multiple sclerosis patients. J Neuroimmunol. 2020;26(346):577307.CrossRef
28.
Huang WC, Lin HC, Yang YH, Hsu CW, Chen NC, Tsai WC, et al. Neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio are associated with a 2-year relapse in patients with multiple sclerosis. Mult Scler Relat Disord. 2022;58:103514.CrossRefPubMed
29.
Li B, Zhou P, Liu Y, Wei H, Yang X, Chen T, et al. Platelet-to-lymphocyte ratio in advanced Cancer: Review and meta-analysis. Clin Chim Acta. 2018;483:48–56.CrossRefPubMed
30.
Ravindra R, Ramamurthy P, Aslam SSM, Kulkarni AKS, Ramamurthy PS. Platelet Indices and Platelet to Lymphocyte Ratio (PLR) as Markers for Predicting COVID-19 Infection Severity. Cureus. 2022;14(8):e28206.PubMedPubMedCentral
31.
Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15(9):545–58.CrossRefPubMed
32.
33.
Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247–69.CrossRefPubMed
34.
Naegele M, Tillack K, Reinhardt S, Schippling S, Martin R, Sospedra M. Neutrophils in multiple sclerosis are characterized by a primed phenotype. J Neuroimmunol. 2012;242(1–2):60–71.CrossRefPubMed
35.
Schett G. Rheumatoid arthritis and multiple sclerosis: direful siblings, different strategies. FEBS letters. 2011;585(239):3601–2.CrossRefPubMed
36.
Gianni M, Annunziata P. Sjögren syndrome and multiple sclerosis: Two sides of the same coin? Autoimmunity Reviews. 2016;15(5):457–61.CrossRef
37.
Pierson ER, Wagner CA, Goverman JM. The contribution of neutrophils to CNS autoimmunity. Clin Immunol. 2018;189:23–8.CrossRefPubMed
38.
Prineas JW, Kwon EE, Cho ES, Sharer LR, Barnett MH, Oleszak EL, et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol. 2001;50(5):646–57.CrossRefPubMed
39.
Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4:43.CrossRefPubMed
40.
Kihara Y, Ishii S, Kita Y, Toda A, Shimada A, Shimizu T. Dual phase regulation of experimental allergic encephalomyelitis by platelet-activating factor. J Exp Med. 2005;202(6):853–63.CrossRefPubMedPubMedCentral
41.
Callea L, Arese M, Orlandini A, Bargnani C, Priori A, Bussolino F. Platelet activating factor is elevated in cerebral spinal fluid and plasma of patients with relapsing-remitting multiple sclerosis. J Neuroimmunol. 1999;94(1–2):212–21.CrossRefPubMed
42.
Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, et al. Genemicroarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med. 2002;8(5):500–8.CrossRefPubMed
43.
Sotnikov I, Veremeyko T, Starossom SC, Barteneva N, Weiner HL, Ponomarev ED. Platelets Recognize Brain-Specific Glycolipid Structures, Respond to Neurovascular Damage and Promote. Neuroinflammation. 2014;9(1):10.1371.
44.
Hou D, Wang C, Luo Y, Ye X, Han X, Feng Y, et al. Systemic immune inflammation index (SII) but not platelet-albumin-bilirubin (PALBI) grade is associated with severity of acute ischemic stroke (AIS). Int J Neurosci. 2021;131(12):1203–8.CrossRefPubMed
45.
Trifan G, Testai FD. Systemic immune-inflammation (SII) index predicts poor outcome after spontaneous supratentorial intracerebral hemorrhage. J Stroke Cerebrovasc Dis. 2020;29(9):105057.CrossRefPubMed
46.
Li S, Liu K, Gao Y, Zhao L, Zhang R, Fang H, et al. Prognostic value of systemic immune–inflammation index in acute/subacute patients with cerebral venous sinus thrombosis. Stroke Vasc Neurol. 2020;5(4):368–73.CrossRefPubMedPubMedCentral
47.
Wu X, Wang H, Xie G, Lin S, Ji C. Increased systemic immune-inflammation index can predict respiratory failure in patients with Guillain-Barré syndrome. Neurol Sci. 2022;43(2):1223–31.CrossRefPubMed
48.
Li S, Zhang Q, Gao Y, Nie K, Liang Y, Zhang Y, et al. Serum Folate, Vitamin B12 Levels, and Systemic Immune-Inflammation Index Correlate With Motor Performance in Parkinson Disease: A Cross-Sectional Study. Front Neurol. 2021;12:665075.CrossRefPubMedPubMedCentral
49.
Gulani V, Calamante F, Shellock FG, Kanal E, Reeder SB. Gadolinium deposition in the brain: summary of evidence and recommendations. Lancet Neurol. 2017;16(7):564–70.CrossRefPubMed
Metadata
Title
The role of systemic ımmune ınflammatory ındex in showing active lesion ın patients with multiple sclerosis
SII and other inflamatuar biomarker in radiological active multiple sclerosis patients
Authors
Seyda Figul Gokce
Asli Bolayır
Burhanettin Cigdem
Bulent Yildiz
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2023
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-023-03101-0

Other articles of this Issue 1/2023

BMC Neurology 1/2023 Go to the issue

Case report

Parkinsonism after ventriculoperitoneal shunt for hydrocephalus

Research

Ultrasound measurement of optic nerve sheath diameter in a healthy adult Colombian population

Correction

Correction to: Hypoxia treatment of Parkinson’s disease may disrupt the circadian system

Correction

Correction: Correlation of serum complement factor 5a level with inflammatory response and cognitive function in patients with Alzheimer’s disease of different severity

Research

Effect of leukoaraiosis on collateral circulation in acute ischemic stroke treated with endovascular therapy: a meta-analysis

Study protocol

Protocol of a randomized controlled trial investigating Deep Brain Stimulation for MOtor symptoms in patients with Parkinson’s disease DEmentia (DBS-MODE)